Literature DB >> 26567156

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.

Marta Libura1, Sebastian Giebel2, Beata Piatkowska-Jakubas3, Marta Pawelczyk1, Izabella Florek3, Karolina Matiakowska4, Bozena Jazwiec5, Katarzyna Borg6, Iwona Solarska6, Magdalena Zawada3, Sylwia Czekalska3, Jolanta Libura1, Malgorzata Jakobczyk3, Karolina Karabin1, Monika Paluszewska1, Malgorzata Calbecka7, Justyna Gajkowska-Kulik7, Grazyna Gadomska8, Marek Kielbinski5, Anna Ejduk6, Dariusz Kata9, Sebastian Grosicki10, Agnieszka Wierzbowska11, Slawomira Kyrcz-Krzemien9, Krzysztof Warzocha6, Kazimierz Kuliczkowski5, Aleksander Skotnicki3, Jerzy Holowiecki2, Wieslaw Wiktor Jedrzejczak1, Olga Haus12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26567156     DOI： 10.1182/blood-2015-08-662130

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

Review 1.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

2.  Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.

Authors:  Patrick K Reville; Koji Sasaki; Hagop M Kantarjian; Naval G Daver; Musa Yilmaz; Courtney D Dinardo; Nicholas J Short; Gautam Borthakur; Naveen Pemmaraju; Rohtesh S Mehta; Sherry Pierce; Sergej N Konoplev; Joseph D Khoury; Guillermo Garcia-Manero; Marina Y Konopleva; Elias Jabbour; Farhad Ravandi; Tapan M Kadia
Journal:  Am J Hematol       Date:  2022-01-08       Impact factor: 10.047

Review 3.  Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.

Authors:  Hagop Kantarjian; Nicholas J Short; Courtney DiNardo; Eytan M Stein; Naval Daver; Alexander E Perl; Eunice S Wang; Andrew Wei; Martin Tallman
Journal:  Lancet Haematol       Date:  2021-10-20       Impact factor: 18.959

4.  IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.

Authors:  Marta Libura; Emilia Bialopiotrowicz; Sebastian Giebel; Agnieszka Wierzbowska; Gail J Roboz; Beata Piatkowska-Jakubas; Marta Pawelczyk; Patryk Gorniak; Katarzyna Borg; Magdalena Wojtas; Izabella Florek; Karolina Matiakowska; Bozena Jazwiec; Iwona Solarska; Monika Noyszewska-Kania; Karolina Piechna; Magdalena Zawada; Sylwia Czekalska; Zoriana Salamanczuk; Karolina Karabin; Katarzyna Wasilewska; Monika Paluszewska; Elzbieta Urbanowska; Justyna Gajkowska-Kulik; Grazyna Semenczuk; Justyna Rybka; Tomasz Wrobel; Anna Ejduk; Dariusz Kata; Sebastian Grosicki; Tadeusz Robak; Agnieszka Pluta; Agata Kominek; Katarzyna Piwocka; Karolina Pyziak; Agnieszka Sroka-Porada; Anna Wrobel; Agnieszka Przybylowicz; Marzena Wojtaszewska; Krzysztof Lewandowski; Lidia Gil; Agnieszka Piekarska; Wanda Knopinska; Lukasz Bolkun; Krzysztof Warzocha; Kazimierz Kuliczkowski; Tomasz Sacha; Grzegorz Basak; Wieslaw Wiktor Jedrzejczak; Jerzy Holowiecki; Przemysław Juszczynski; Olga Haus
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.996

5.  Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.

Authors:  Jun Yang; Yu Cai; JieLing Jiang; LiPing Wan; HaiTao Bai; Jun Zhu; Su Li; Chun Wang; Xianmin Song
Journal:  Ann Hematol       Date:  2017-12-18       Impact factor: 3.673

6.  FLT3 inhibitor design using molecular docking based virtual screening for acute myeloid leukemia.

Authors:  Padmini Gokhale; Aashish Pratap Singh Chauhan; Anushka Arora; Natasha Khandekar; Anuraj Nayarisseri; Sanjeev Kumar Singh
Journal:  Bioinformation       Date:  2019-02-28

Review 7.  Acute myeloid leukemia: current progress and future directions.

Authors:  Hagop Kantarjian; Tapan Kadia; Courtney DiNardo; Naval Daver; Gautam Borthakur; Elias Jabbour; Guillermo Garcia-Manero; Marina Konopleva; Farhad Ravandi
Journal:  Blood Cancer J       Date:  2021-02-22       Impact factor: 11.037

8.  Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair.

Authors:  Julio Castaño; Ana B Herrero; Aldeheid Bursen; Federico González; Rolf Marschalek; Norma C Gutiérrez; Pablo Menendez
Journal:  Oncotarget       Date:  2016-05-24

9.  Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.

Authors:  Anna B Halpern; Megan Othus; Emily M Huebner; Bart L Scott; Pamela S Becker; Mary-Elizabeth M Percival; Paul C Hendrie; Kelda M Gardner; Tara L Chen; Sarah A Buckley; Kaysey F Orlowski; Asma Anwar; Frederick R Appelbaum; Harry P Erba; Elihu H Estey; Roland B Walter
Journal:  Leukemia       Date:  2018-04-17       Impact factor: 11.528

Review 10.  FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.

Authors:  Naval Daver; Sangeetha Venugopal; Farhad Ravandi
Journal:  Blood Cancer J       Date:  2021-05-27       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.